PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Iksuda Therapeutics exercises licensing rights from University of Goettingen

UK-based biotech company Iksuda Therapeutics has executed its option to secure exclusive worldwide rights to develop a new class of tumour-activated prodrug payloads from the University of Goettingen.

This comes following a successful collaboration between the two parties which exemplified the series in antibody drug conjugate (ADC) formats.

Iksuda will advance development and commercialisation of the new class within its pipeline to create new ADC therapeutics for nominated targets associated with haematological and solid tumours with high unmet needs.

Iksuda’s partnership with the University of Goettingen confirmed the value of tumour-selective activation of cytotoxic agents, conjugated with Iksuda’s stable conjugation technology in the therapeutic index of ADCs.

“Iksuda’s successful partnership with the University of Goettingen, led by Professor Lutz Tietze, and subsequent licensing agreement demonstrates our continued work in building and refining approaches to ADC development,” said Dave Simpson, chief executive officer, Iksuda Therapeutics.

“We are successfully responding to the industry-wide challenge of being able to treat all patients with cancer.

“Iksuda remains focused on building a pipeline of next-generation ADCs with improved therapeutic index through our internal and external pipeline, harnessing our deep understanding in the field and accepting the challenge of targeting areas of high unmet clinical need,” he added

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026